Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy
Hosted by Jingyi Liu August 3, 2022 Hong Tang Biography Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality...
top of page
Newsroom
Jun 29, 2022
Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies
Hosted by Joe Varriale June 30, 2022 Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted...
Jun 14, 2022
Fierce Biotech I After 3 years away, BIO marked by first-time handshakes
Written by Max Bayer June 15, 2022 Six days after the World Health Organization officially declared COVID-19 a global pandemic on March...
May 31, 2022
BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolved
Source: https://www.biospectrumasia.com/e-magazine By Dr. Manbeena Chawla June 2022 Although there has been tremendous progress in...
May 27, 2022
OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding
View on PRNewswire - Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for...
May 17, 2022
Podcast: Leading without the Title: Becoming a Natural Leader – with Hong Tang
Source: https://brilliancewithincoaching.com/podcast/leading-without-the-title-becoming-a-natural-leader-with-hong-tang/ Hong Tang is the...
Mar 8, 2022
OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel CID Therapeutic, at AACR
- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...
Mar 1, 2022
Informa I Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease By Eleanor Malone March 1, 2022 Executive Summary Evolving challenges...
Feb 14, 2022
OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey at ASCO GU
- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...
Feb 2, 2022
GEN | Supportive Care: OnQuality Treats Cancer’s Side Effects
Written by Alex Philippidis February 2, 2022 OnQuality recently announced positive news for its lead candidate OQL011, an ointment...
bottom of page